Retatrutide is an investigational weight-loss medication. It has no FDA-approved labeling or indication in the United States. It is still in clinical trials. It is not commercially available, and it is not something we offer yet. We are covering it early because the search interest is real and the science is genuinely interesting — but there is no version of this drug you can be prescribed today, from us or anyone else. This is education for now, so that if and when retatrutide is approved, you already know where to find it.
If you're new to this whole category, our overview of weight-loss shots explained is a calmer starting point, since those medications (unlike retatrutide) are actually available through a licensed clinician.
What is retatrutide?
Retatrutide is an investigational, once-weekly injectable being studied by Eli Lilly[1]. Retatrutide is often called a "triple agonist" because it targets three hormone receptors at once — GIP, GLP-1, and glucagon[1]. Semaglutide is a single GLP-1 receptor agonist[2]. Tirzepatide is a dual GIP/GLP-1 agonist[3]. Retatrutide's mechanism is a step further. Retatrutide is not FDA-approved[4].
Is retatrutide FDA-approved or available yet?
No. Retatrutide is not FDA-approved for weight loss or any other use. You can't get it by prescription, from a pharmacy, or through any telehealth service — including ours. Because retatrutide has no FDA-approved labeling, any product sold to consumers as "retatrutide" is not an approved prescription drug[5]. Products sold that way sit outside the licensed pharmacy supply chain entirely — which is exactly why we'd tell you to stay away from them.
Thinking about buying retatrutide online?
It's sold all over as a "research chemical," shipped cheap — but no website can prove what's actually in the vial. Retatrutide is still investigational and can't be legally compounded, and independent testing of this channel found online-bought GLP-1 far below its labeled purity and contaminated in every sample. Before you consider it, read what you'd actually be risking — and how the gray market differs from a prescription filled by a licensed pharmacy — in Retatrutide for sale: what you're actually putting in your body →.
How does retatrutide compare to semaglutide and tirzepatide?
The honest answer: you can't compare them the way you'd compare two approved drugs, because retatrutide hasn't finished the trials that would make that comparison fair. What we can say is mechanistic. Semaglutide is a single GLP-1 receptor agonist. Tirzepatide is a dual GIP/GLP-1 agonist. Retatrutide adds a third target, glucagon-receptor activity, alongside GIP and GLP-1 receptor agonism. Retatrutide's weight-loss numbers looked large — but a 2025 network meta-analysis comparing retatrutide, tirzepatide, and semaglutide (Yan K, Acta Diabetologica, 2025) had to rely on indirect comparisons[6], and concluded that direct head-to-head trials are needed to confirm its results. If you want an apples-to-apples look at two medications that are available and have been compared, read semaglutide vs tirzepatide instead. The retatrutide-vs-tirzepatide and retatrutide-vs-semaglutide conversations are, for now, speculative.
What did the retatrutide trials show?
The most-cited data come from retatrutide's phase 2 trial in adults with obesity (Jastreboff AM, NEJM, 2023). In its phase 2 trial, retatrutide produced substantial reductions in body weight in adults, with larger reductions at higher doses[1]. That's a promising signal for a triple-agonist approach to weight loss. But context matters: phase 2 is a mid-stage trial in a limited group of people — a read on whether a drug is worth taking further, not the final word on how it performs in the real world. Larger, longer phase 3 trials are what regulators lean on. Retatrutide is now being studied in phase 3 trials, including a completed 40-week phase 3 trial in adults with type 2 diabetes. On side effects: in retatrutide's phase 2 trial, the most common adverse events in the retatrutide groups were gastrointestinal, and they were dose-related and mostly mild to moderate in severity. Retatrutide's phase 2 trial (Jastreboff AM, NEJM, 2023) also recorded dose-dependent increases in heart rate that peaked at 24 weeks and then declined[1]. None of this is settled, and "promising in phase 2" is not the same as "proven and safe." Individual results vary, and in an investigational drug they vary a great deal.
When will retatrutide be available?
There's no confirmed availability date. Retatrutide is still moving through the clinical-trial process. Any FDA submission and review would come only after those trials are complete and analyzed. Timelines for investigational drugs routinely shift, and some never reach approval at all. The truthful answer is: not now, and no one can responsibly promise a date.
So where does that leave you if you're interested in medical weight care today? With options that already exist and are overseen by licensed clinicians — not with a drug that's still being tested. The category of GLP-1 and dual-agonist therapy is covered on our weight wellness hub, and whether any medication fits your health history is a decision for a licensed clinician, not a search result. Retatrutide, for the moment, belongs in the "one to watch" column — an interesting entry in the triple-agonist weight-loss story that hasn't finished being written.
A note on why we're covering an unavailable drug
Because you're already searching for it. Our job is to give you accurate, non-hyped information before the internet fills with hype. Retatrutide's early data are real and worth understanding — and so is the plain fact that it isn't approved, isn't available, and isn't sold by anyone legitimately. Both things are true at once, and we'd rather you hear that from a source that isn't trying to sell it to you. And if and when retatrutide is approved and available, this is the page we'll update — same place, with the how-to-get-started details added — so the explainer you trusted becomes the trusted place to begin.
FAQ
Can I buy retatrutide right now?
No. Retatrutide is not FDA-approved. It is still in clinical trials. It isn't available by prescription or through any pharmacy or telehealth service, including ours. Anything marketed to consumers as "retatrutide" is not an approved prescription drug. Products sold that way sit outside the licensed pharmacy supply chain.
Is retatrutide better than tirzepatide or semaglutide?
There's no reliable head-to-head answer yet. Retatrutide targets three receptors, tirzepatide two, and semaglutide one. In its phase 2 trial, retatrutide produced substantial reductions in body weight in adults. But a 2025 network meta-analysis comparing retatrutide, tirzepatide, and semaglutide (Yan K, Acta Diabetologica, 2025) had to rely on indirect comparisons and concluded that direct head-to-head trials are needed to confirm its results — so "better" isn't established, and mid-stage numbers don't confirm long-term safety or real-world effectiveness. Individual results vary.
What are the known retatrutide side effects?
In retatrutide's phase 2 trial, the most common adverse events in the retatrutide groups were gastrointestinal, and they were dose-related and mostly mild to moderate in severity[1]. Retatrutide's phase 2 trial (Jastreboff AM, NEJM, 2023) also recorded dose-dependent increases in heart rate that peaked at 24 weeks and then declined. Because retatrutide is still investigational, its full side-effect and safety profile isn't established[1].
What does "triple agonist" mean?
It means retatrutide is designed to activate three hormone receptors — GIP, GLP-1, and glucagon — at the same time. The added glucagon-receptor activity, alongside GIP and GLP-1 receptor agonism, is what separates it from tirzepatide (dual) and semaglutide (single).
When will retatrutide be approved?
Unknown. It still needs to complete late-stage trials before any potential FDA review, and investigational-drug timelines frequently change. No credible source can give you a confirmed approval or availability date right now.
Ladies First provides marketing/advertising services. Medical services are provided by our medical provider partner, an independent network of US-licensed medical providers. All medical decisions are made by a medical provider licensed in your state. This article is for general information and is not medical advice — talk to a licensed clinician about your situation. Individual results vary. Retatrutide is investigational and not FDA-approved. Ozempic®/Wegovy® are registered trademarks of Novo Nordisk; Mounjaro®/Zepbound® are registered trademarks of Eli Lilly; retatrutide is an Eli Lilly investigational compound. Brand names are used for identification only.